Evaluation of apolipoprotein A1, apolipoprotein b levels in the blood serum and their ratio in young adults with untreated somatotropic deficiency appeared in childhood
DOI:
https://doi.org/10.15587/2519-4798.2016.77799Keywords:
somatotropic deficiency, appeared in childhood, young adults, apolipoprotein A1, apolipoprotein BAbstract
There was studied the content of apolipoproteins А1 (ApоА1) and apolipoproteins B (ApoВ) in the blood serum and their ratio in young adults ( mean age 22,47±0,30 years) with somatotropic deficiency, appeared in childhood. In most patients, who did not receive treatment with preparations of recombinant growth hormone (rGH) the undesirable changes of the lipid profile were established, especially the essential decrease of apolipoproteins A1 level and increase of apolipoproteins B level, disturbance of their ratio that favors the significant growth of cardiovascular risk.
Aim. Determination of the presence of cardio-vascular risk factors in young adults with prolonged deficiency of growth hormone by the study of apolipoprotein А1, apolipoprotein В in the blood and their ratio.
Methods. АpоА1 and АpоВ levels in the blood serum were determined by immunoturbidimetric method (Cobas 6000; RocheDiagnostics, Switzerland). The level of insulin-like growth factor (IGF) in the blood plasma was determined by radioimmunological method using the standard sets «IRMAIGF-1" («Immunotech» , Czech Republic). The measuring of height was carried out using stadiometer «SystemDr.KellerJ.», body mass was measured using electronic weigher Tanita BC587 (Japan). The bone age was determined by the atlas W. W. Greulich & S. P. Pyle (1993). The materials of Register of patients with somatotropic deficiency, created on the base of the department of child endocrine pathology of SI “Institute of endocrinology and metabolism, named after V. P. Komissarenko, NAMS of Ukraine” were used in the work.
Statistical processing of the results was carried out using Microsoft Excel statistical programs with the help of methods of variation statistics. The results were presented as the mean values and their standard mistake (M±m). The assessment of statistical reliability was realized by Student parametric t-criterion. The difference between results was considered as a reliable one at р<0,05.
Results of research. 174 patients with somatotropic deficiency, appeared in the childhood, were examined. Mean age was 22,47±0,30 years ( in women – 23,47±0,61 years; in men – 22,03±0,32 years). The height of patients was 138,0 – 174,0 cm, body mass index – from 19,2 to 33,3. Under conditions of prolonged deficiency of growth hormone only 17.8 % of patients had АpоА1 parameters within the norm and 67,2 % – the normal АpоВ parameters in the blood serum.
The mean level of ApoA1 in the blood serum of young adults was reliably lower than the control parameters (0,88±0,014 g/l and 1,21±0,018 g/l respectively, p<0.001). At the same time the mean ApoB level essentially exceeded the parameters in the control group (1,171±0,022g/l and 0,995±0,028 g/l, respectively, p<0.001). ApoB / ApoA1 ratio exceeded the value 1 and was 1,366±0,028 (in the control group 0,816±0,016, p<0.001). The essential gender differences in parameters of АpоА1,АpоВ and АpоВ/АpоА1 in young adults with somatotropic deficiency, who did not receive treatment with rGH, were not found.
Conclusion. There were established the significant undesirable changes of the levels of apolipoproteins А1, apolipoproteins B in the blood serum and disturbance of their ratio in young adults with somatotropic deficiency, appeared in childhood. The received data testify to the accumulation of cardiovascular risk factors in young adults under conditions of prolonged deficiency of growth hormones and the necessity of continuation/renewal of therapy with preparations of recombinant growth hormoneReferences
- Devesa, J., Devesa, P., Reimunde, P. (2010). Hormona de crecimiento: acciones y aplicaciones preventivas y terapéuticas. Medicina Clínica, 135 (14), 665–670. doi: 10.1016/j.medcli.2009.10.017
- Steyn, F. J., Tolle, V., Chen, C., Epelbaum, J. (2016). Neuroendocrine Regulation of Growth Hormone Secretion. Comprehensive Physiology, 687–735. doi: 10.1002/cphy.c150002
- Höybye, C., Christiansen, J. S. (2015). Growth hormone replacement in adults – current standards and new perspectives. Best Practice & Research Clinical Endocrinology & Metabolism, 29 (1), 115–123. doi: 10.1016/j.beem.2014.09.006
- Wu, J. F., Tang, Y. Y., Zeng, G. F., Tang, C. K. (2014). Role of apolipoprotein AI on nascent high-density lipoprotein particle formation. Sheng Li KeXueJin Zhan, 45 (2), 81–86.
- Dominiczak, M. H., Caslake, M. J. (2011). Apolipoproteins: metabolic role and clinical biochemistry applications. Annals of Clinical Biochemistry, 48 (6), 498–515. doi: 10.1258/acb.2011.011111
- Verhelst, J., Abs, R. (2009). Cardiovascular risk factors in hypopituitary GH-deficient adults. European Journal of Endocrinology, 161, S41–S49. doi: 10.1530/eje-09-0291
- Kokshoorn, N. E., Biermasz, N. R., Roelfsema, F., Smit, J. W. A., Pereira, A. M., Romijn, J. A. (2011). GH replacement therapy in elderly GH-deficient patients: a systematic review. European Journal of Endocrinology, 164 (5), 657–665. doi: 10.1530/eje-10-1170
- Appelman-Dijkstra, N. M., Claessen, K. M. J. A., Roelfsema, F., Pereira, A. M., Biermasz, N. R. (2013). Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. European Journal of Endocrinology, 169 (1), R1–R14. doi: 10.1530/eje-12-1088
- Khadilkar, V., Ekbote, V., Kajale, N., Khadilkar, A., Chiplonkar, S., Kinare, A. (2013). Effect of one-year growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency. Endocrine Research, 39 (2), 74–79. doi: 10.3109/07435800.2013.828742
- Knop, C., Wolters, B., Lass, N., Wunsch, R., Reinehr, T. (2015). Carotid intima-media thickness in children treated with growth hormone. Journal of Pediatric Endocrinology and Metabolism, 28 (9-10). doi: 10.1515/jpem-2014-0180
- Karavia, E. A., Zvintzou, E., Petropoulou, P.-I., Xepapadaki, E., Constantinou, C., Kypreos, K. E. (2014). HDL quality and functionality: what can proteins and genes predict? Expert Review of Cardiovascular Therapy, 12 (4), 521–532. doi: 10.1586/14779072.2014.896741
- Helkin, A., Stein, J. J., Lin, S., Siddiqui, S., Maier, K. G., Gahtan, V. (2016). Dyslipidemia Part 1 – Review of Lipid Metabolism and Vascular Cell Physiology. Vascular and Endovascular Surgery, 50 (2), 107–118. doi: 10.1177/1538574416628654
- Sahebkar, A., Watts, G. F. (2013). New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes. Clinical Therapeutics, 35 (8), 1082–1098. doi: 10.1016/j.clinthera.2013.06.019
- Russell-Jones, D. L., Watts, G. F., Welssberger, A., Naoumova, R., Myers, J., Thompson, G. R., Sönksen, P. H. (1994). The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology, 41 (3), 345–350. doi: 10.1111/j.1365-2265.1994.tb02555.x
- Ho, K. K. Y. (2007). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. European Journal of Endocrinology, 157 (6), 695–700. doi: 10.1530/eje-07-0631
- Bollerslev, J. (2006). Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. European Journal of Endocrinology, 154 (4), 537–543. doi: 10.1530/eje.1.02125
- Ciresi, A., Amato, M. C., Criscimanna, A., Mattina, A., Vetro, C., Galluzzo, A. et. al. (2007). Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. European Journal of Endocrinology, 156 (3), 353–360. doi: 10.1530/eje.1.02343
- Johannsson, G. (2000). What Happens When Growth Hormone is Discontinued at Completion of Growth? Metabolic Aspects. Journal of Pediatric Endocrinology and Metabolism, 13. doi: 10.1515/jpem-2000-s603
- Lanes, R. (2016). Cardiovascular Risk in Growth Hormone Deficiency. Endocrinology and Metabolism Clinics of North America, 45 (2), 405–418. doi: 10.1016/j.ecl.2016.01.005
- Metwalley, K., Farghaly, H., Abd El-Hafeez, H. (2013). Evaluation of left ventricular mass and function, lipid profile, and insulin resistance in Egyptian children with growth hormone deficiency: A single-center prospective case-control study. Indian Journal of Endocrinology and Metabolism, 17 (5), 876. doi: 10.4103/2230-8210.117234
- Lobo, P. M., Conceição, F. L., Soares, D. V., Spina, L. D. C., Brasil, R. R. L. O., Silva, E. M. C. da, Vaisman, M. (2005). Perfil lipídico e composição corporal na deficiência do hormônio de crescimento em adultos. Revista da Associação Médica Brasileira, 51 (5), 265–269. doi: 10.1590/s0104-42302005000500017
- Abdu, T. A. M., Neary, R., Elhadd, T. A., Akber, M., Clayton, R. N. (2001). Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clinical Endocrinology, 55 (2), 209–216. doi: 10.1046/j.1365-2265.2001.01320.x
- Monson, J. P., Brooke, A. M., Akker, S.; De Groot, L. J., Beck-Peccoz, P., Chrousos, G., Dungan, K., Grossman, A., Hershman, J. M. et. al. (Eds.) (2015). Adult Growth Hormone Deficiency. South Dartmouth (MA): MDText.com, Inc.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Тетяна Олександрівна Ткачова, Ольга Анатоліївна Вишневська, Олена Василівна Большова
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.